US9427354B2ActiveUtilityA1

Material for medical use comprising nanoparticles with superparamagnetic properties and its utilization in surgery

Assignee: ZYSLER ROBERTOPriority: Sep 20, 2010Filed: Sep 9, 2011Granted: Aug 30, 2016
Est. expirySep 20, 2030(~4.2 yrs left)· nominal 20-yr term from priority
A61L 27/54A61L 2300/44A61F 9/007A61K 9/0051A61F 9/00727A61P 27/02A61K 9/5094A61L 2400/06A61L 27/042A61K 9/0048A61K 9/5146A61K 9/5115A61L 2400/12A61L 2430/16
30
PatentIndex Score
0
Cited by
21
References
4
Claims

Abstract

This invention relates to a material for medical use that comprises biocompatible nanoparticles having superparamagnetic properties, where the superparamagnetic properties of said nanoparticles are used to localize their action on a determined space or tissue. In particular, said nanoparticles having superparamagnetic properties are composed of magnetite. The material according to the invention has various applications, both in surgical and in therapeutic treatments.

Claims

exact text as granted — not AI-modified
What it is claimed is: 
     
       1. A procedure for tamponading a patient's retina, comprising the following steps in order:
 i. submitting the patient to a vitrectomy; 
 ii. injecting a material into the patient's intravitreous space, wherein the material is in the form of a liquid suspension comprising biocompatible nanoparticles having superparamagnetic properties, and the liquid suspension does not contain a polymeric material; and 
 iii. through application of a magnetic field created by a magnet located outside the eye, attract the nanoparticles to push and maintain the retina applied against an inner wall of the patient's eye,
 wherein a step of polymerizing the nanoparticles does not take place between steps ii and iii. 
 
 
     
     
       2. The procedure according to  claim 1 , wherein the nanoparticles may exert their action equally for upper injuries and for lower injuries. 
     
     
       3. The procedure according to  claim 2 , wherein the nanoparticles are injected together with a pharmaceutically acceptable vehicle or carrier contained in the liquid suspension or in a composition separate from the liquid suspension. 
     
     
       4. The procedure of  claim 1 , further comprising the steps of
 iv. removing the magnetic field applied in step iii, 
 v. allowing the nanoparticles to be absorbed by the patient's eye tissue.

Join the waitlist — get patent alerts

Track US9427354B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.